| Hint | Antwort | % Korrekt |
|---|---|---|
| Rituximab | CD20 | 100%
|
| Alemtuzumab | CD52 | 100%
|
| Adalimumab | TNFa | 100%
|
| Cetuximab | EGFR | 100%
|
| Burosumab | FGF23 | 100%
|
| Trastuzumab | HER2 | 100%
|
| Omalizumab | IgE | 100%
|
| canakinumab | IL1 | 100%
|
| Pembrolizumab | PD1 | 100%
|
| Bevacizumab | VEGF | 100%
|
| Abatacept | CD80/86 | 50%
|
| Basilixumab | CD25 | 0%
|
| Ipilimumab | CTLA4 | 0%
|
| Relatlimab | LAG3 | 0%
|
| Natalizumab | Integrin-a4 | 0%
|